A Phase 1 interventional study of GC1130A in Sanfilippo Syndrome Type A, sponsored by GC Biopharma Corp. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by GC Biopharma Corp · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.
Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 17th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1, reaches primary completion later than 5 of the 14 other live ones, and was the 39th registered.
58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.
Browse Mucopolysaccharidosis III studies →12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Sites in United States
Ages 4+
Ozlem Goker-Alpan · Sites in United States
Ages 18–99
Phoenix Nest · Sites in United States, France
Ages 12 mo+
Denali Therapeutics Inc. · Sites in United States
Ages 0–18
Lysosomal and Rare Disorders Research and Treatment Center, Inc. · Sites in United States
Ages 5–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 12 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 18 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9 is below the median of 12 across 33 interventional studies indexed under Mucopolysaccharidosis III.
Median enrollment 17 across the 23 interventional studies, 30 across the 19 observational. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under GC Biopharma Corp, one of the names counted as GC Biopharma Corp.. Under that name alone:
GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
GC Biopharma Corp. has 1 study filed under Mucopolysaccharidosis III — fewer than ten, so there is no comparison to draw.
5 of the studies in Mucopolysaccharidosis III with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06333041Phase 3Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterStudy of Cannabidiol in Sanfilippo Syndrome | 2027-04 |
| NCT04360265Phase 3Ultragenyx Pharmaceutical IncFollow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA | 2027-08 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06567769GC Biopharma CorpPhase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) | 2027-06 |
| NCT05492799Allievex CorporationSafety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Mucopolysaccharidosis III with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GC1130A
Drug: GC1130A
Drug: GC1130A
ICV injection
Incidences and characteristics of adverse events
Time frame: up to 108 weeks
Maximum concentration in cerebrospinal fluid (CSF)
GC1130A PK parameters
Time frame: up to 104 weeks
Area under the concentration-time curve in CSF
GC1130A PK parameters
Time frame: up to 104 weeks
Maximum concentration in serum
GC1130A PK parameters
Time frame: up to 104 weeks
Area under the concentration-time curve in serum
GC1130A PK parameters
Time frame: up to 104 weeks
Change from baseline in CSF heparan sulfate concentration
Time frame: up to 104 weeks
Change from baseline in serum heparan sulfate concentration
Time frame: up to 104 weeks
Incidence of anti-drug and neutralizing antibodies of GC1130A in CSF
Time frame: up to 104 weeks
Incidence of anti-drug and neutralizing antibodies of GC1130A in serum
Time frame: up to 104 weeks
Change from baseline in raw scores in cognitive domain of Bayley Scales of Infant and Toddler Development Scores-3rd edition (BSID-III)
Time frame: up to 104 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.